HC Wainwright Issues Positive Outlook for AARD Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Aardvark Therapeutics to a loss of $0.55 per share from a previous estimate of $0.94, while maintaining a Neutral rating and $4.00 price target.
• Analyst sentiment remains mixed: Aardvark has an overall MarketBeat consensus rating of Hold and an average price target of $11.89, despite several Buy, Hold, and Sell ratings.
• AARD shares opened at $3.90, near their one-year low of $3.35 and well below the one-year high of $16.60. The company most recently reported a quarterly loss of $0.66 per share, beating consensus estimates for a $0.87 loss.

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Investment analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Aardvark Therapeutics in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.55) per share for the quarter, up from their previous estimate of ($0.94). HC Wainwright has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Aardvark Therapeutics' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Aardvark Therapeutics' Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.69) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.74) EPS.

Several other research firms also recently commented on AARD. BTIG Research reissued a "neutral" rating on shares of Aardvark Therapeutics in a research note on Monday, October 12th. Wall Street Zen raised shares of Aardvark Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a report on Monday. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $6.00 target price on shares of Aardvark Therapeutics in a report on Thursday, September 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Aardvark Therapeutics presently has an average rating of "Hold" and an average target price of $11.89.

Aardvark Therapeutics Price Performance

Shares of NASDAQ:AARD opened at $3.90 on Wednesday. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.60. The firm has a market capitalization of $85.33 million, a PE ratio of -1.21 and a beta of 3.80. The business's 50 day moving average price is $5.45 and its 200-day moving average price is $5.29.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.21.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in Aardvark Therapeutics during the second quarter worth $138,000. J. Goldman & Co LP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $233,000. Ieq Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $221,000. BlackRock Inc. acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $1,077,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Aardvark Therapeutics during the 1st quarter worth $267,000.

Insider Buying and Selling at Aardvark Therapeutics

In other news, insider Nelson Sun sold 62,000 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares in the company, valued at $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 17.80% of the stock is currently owned by corporate insiders.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.